Jupiter Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Jupiter Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,395	Closed	-$230K	–	648
2022 Q1	$230K	Sell	20,395 -1,350	-6%	-$17.7K	﹤0.01%	494
2021 Q4	$341K	Buy	21,745 +6,993	+47%	+$122K	﹤0.01%	504
2021 Q3	$253K	Buy	14,752 +1,350	+10%	+$23.6K	﹤0.01%	526
2021 Q2	$288K	Hold	13,402	–	–	﹤0.01%	544
2021 Q1	$201K	Sell	13,402 -12,923	-49%	-$209K	﹤0.01%	552
2020 Q4	$346K	Buy	+26,325	New	+$317K	﹤0.01%	540

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jupiter Asset Management's VNDA Position: Q2 2022 in Review

Jupiter Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 20,395 shares — an estimated $230K sold.

Jupiter Asset Management first reported a position in VNDA in Q4 2020 and held it in 6 quarters. The position peaked at $346K in Q4 2020. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

Jupiter Asset Management reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Jupiter Asset Management sold 20,395 Vanda Pharmaceuticals shares in Q2 2022, an estimated $230K.
Jupiter Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Jupiter Asset Management's Vanda Pharmaceuticals position peaked at $346K in Q4 2020.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Jupiter Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.